Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma Frederick W. ThielenNasuh C. BüyükkaramikliIsaac Corro Ramos Review Article Open access 13 December 2018 Pages: 975 - 984
Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal Becky PenningtonShije RenSteven J. Edwards Review Article 22 November 2018 Pages: 985 - 993
Cost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature Review Nikolaos ManiadakisEvgenia Konstantakopoulou Systematic Review 22 April 2019 Pages: 995 - 1010
Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review Stuart J. WrightWilliam G. NewmanKatherine Payne Systematic Review Open access 13 May 2019 Pages: 1011 - 1027
The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective Simon FreyTom StargardtJonas Schreyögg Original Research Article 04 April 2019 Pages: 1029 - 1039
A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator’s Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck Kim CocksMarta ContenteJames W. Shaw Original Research Article Open access 10 April 2019 Pages: 1041 - 1047
Is Reclassification of the Oral Contraceptive Pill from Prescription to Pharmacist-Only Cost Effective? Application of an Economic Evaluation Approach to Regulatory Decisions Mutsa GumbieBonny ParkinsonVirginia Mumford Original Research Article 09 May 2019 Pages: 1049 - 1064
Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States” Katrine WallaceSandra GobleJosh Bedel Letter to the Editor Open access 07 June 2019 Pages: 1065 - 1067
Correction to: Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO) Hui ShaoVivian FonsecaLizheng Shi Correction 16 May 2019 Pages: 1069 - 1069
Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia Mark BounthavongJaved ButlerDavid L. Veenstra Correction 14 May 2019 Pages: 1071 - 1071